TY - JOUR
T1 - HYAL-1 Hyaluronidase
T2 - A Potential Prognostic Indicator for Progression to Muscle Invasion and Recurrence in Bladder Cancer
AU - Kramer, Mario W.
AU - Golshani, Roozbeh
AU - Merseburger, Axel S.
AU - Knapp, Judith
AU - Garcia, Alfredo
AU - Hennenlotter, Joerg
AU - Duncan, Robert C.
AU - Soloway, Mark S.
AU - Jorda, Merce
AU - Kuczyk, Marcus A.
AU - Stenzl, Arnulf
AU - Lokeshwar, Vinata B.
N1 - Funding Information:
Funding/Support and role of the sponsor: This work was supported by funding from the NCI grant 2R01CA72821-10A2 (VBL), Florida Bankhead Coley Cancer Research Program grant 08BB-09 (VBL) and University of Miami CURED (MSS). Mario Kramer and Judith Knapp were supported by fellowships from the International Academy of Life Sciences, Biomedical Science Exchange Program.
PY - 2010/1
Y1 - 2010/1
N2 - Background: For bladder cancer (BCa) patients undergoing bladder-sparing treatments, molecular markers may aid in accurately predicting progression to muscle invasion and recurrence. Hyaluronic acid (HA) is a glycosaminoglycan that promotes tumor metastasis. Hyaluronoglucosaminidase 1 (HYAL-1)-type hyaluronidase (HAase) promotes tumor growth, invasion, and angiogenesis. Urinary HA and HAase levels are diagnostic markers for BCa. Objective: We evaluated whether HA and HYAL-1 can predict progression to muscle invasion and recurrence among patients with non-muscle-invasive BCa. Design, setting, and participants: : Based on tissue availability, tissue microarrays were prepared from a cohort of 178 BCa specimens (144 non-muscle invasive, 34 muscle invasive). Follow-up information was available on 111 patients with non-muscle-invasive BCa (mean follow-up: 69.5 mo); 58 patients recurred and 25 progressed to muscle invasion (mean time to progress: 22.3 mo). Measurements: HA and HYAL-1 expression was evaluated by immunohistochemistry and graded for intensity and area of staining. Association of HA and HYAL-1 staining with BCa recurrence and muscle invasion was evaluated by univariate and multivariate models. Results and limitations: HA and HYAL-1 expression correlated with tumor grade, stage, and multifocality (p < 0.05). In non-muscle-invasive BCa specimens, HYAL-1 staining was higher (234.3 ± 52.2; 200.6 ± 61.4) if patients experienced progression to muscle invasion or recurrence when compared with no progression or recurrence (164.1 ± 48.2; 172.1 ± 57; p < 0.001). HA staining correlated with muscle invasion (p < 0.001). In univariate analysis, age (p = 0.014), multifocality (p = 0.023), and HYAL-1 staining (p < 0.001) correlated with muscle invasion, whereas only HYAL-1 correlated with recurrence (p = 0.013). In multivariate analysis, HYAL-1 significantly associated with muscle invasion (p < 0.001; 76.8% accuracy) and recurrence (p = 0.01; 67.8% accuracy). Conclusions: HYAL-1 is a potential prognostic marker for predicting progression to muscle invasion and recurrence.
AB - Background: For bladder cancer (BCa) patients undergoing bladder-sparing treatments, molecular markers may aid in accurately predicting progression to muscle invasion and recurrence. Hyaluronic acid (HA) is a glycosaminoglycan that promotes tumor metastasis. Hyaluronoglucosaminidase 1 (HYAL-1)-type hyaluronidase (HAase) promotes tumor growth, invasion, and angiogenesis. Urinary HA and HAase levels are diagnostic markers for BCa. Objective: We evaluated whether HA and HYAL-1 can predict progression to muscle invasion and recurrence among patients with non-muscle-invasive BCa. Design, setting, and participants: : Based on tissue availability, tissue microarrays were prepared from a cohort of 178 BCa specimens (144 non-muscle invasive, 34 muscle invasive). Follow-up information was available on 111 patients with non-muscle-invasive BCa (mean follow-up: 69.5 mo); 58 patients recurred and 25 progressed to muscle invasion (mean time to progress: 22.3 mo). Measurements: HA and HYAL-1 expression was evaluated by immunohistochemistry and graded for intensity and area of staining. Association of HA and HYAL-1 staining with BCa recurrence and muscle invasion was evaluated by univariate and multivariate models. Results and limitations: HA and HYAL-1 expression correlated with tumor grade, stage, and multifocality (p < 0.05). In non-muscle-invasive BCa specimens, HYAL-1 staining was higher (234.3 ± 52.2; 200.6 ± 61.4) if patients experienced progression to muscle invasion or recurrence when compared with no progression or recurrence (164.1 ± 48.2; 172.1 ± 57; p < 0.001). HA staining correlated with muscle invasion (p < 0.001). In univariate analysis, age (p = 0.014), multifocality (p = 0.023), and HYAL-1 staining (p < 0.001) correlated with muscle invasion, whereas only HYAL-1 correlated with recurrence (p = 0.013). In multivariate analysis, HYAL-1 significantly associated with muscle invasion (p < 0.001; 76.8% accuracy) and recurrence (p = 0.01; 67.8% accuracy). Conclusions: HYAL-1 is a potential prognostic marker for predicting progression to muscle invasion and recurrence.
KW - Bladder cancer
KW - HYAL-1
KW - Hyaluronic acid
KW - Hyaluronidase
KW - Non-muscle-invasive bladder cancer
KW - Prognostic markers
KW - Tissue microarray
UR - http://www.scopus.com/inward/record.url?scp=70449535869&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70449535869&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2009.03.057
DO - 10.1016/j.eururo.2009.03.057
M3 - Article
C2 - 19345473
AN - SCOPUS:70449535869
SN - 0302-2838
VL - 57
SP - 86
EP - 94
JO - European urology
JF - European urology
IS - 1
ER -
